GEP20257840B - Tyk2 pseudokinase ligands - Google Patents
Tyk2 pseudokinase ligandsInfo
- Publication number
- GEP20257840B GEP20257840B GEAP202015969A GEAP2020015969A GEP20257840B GE P20257840 B GEP20257840 B GE P20257840B GE AP202015969 A GEAP202015969 A GE AP202015969A GE AP2020015969 A GEAP2020015969 A GE AP2020015969A GE P20257840 B GEP20257840 B GE P20257840B
- Authority
- GE
- Georgia
- Prior art keywords
- ligands
- tyk2 pseudokinase
- tyk2
- pseudokinase ligands
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933179P | 2019-11-08 | 2019-11-08 | |
| US202063046514P | 2020-06-30 | 2020-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20257840B true GEP20257840B (en) | 2025-12-25 |
Family
ID=75846491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202015969A GEP20257840B (en) | 2019-11-08 | 2020-11-05 | Tyk2 pseudokinase ligands |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11753411B2 (enExample) |
| EP (1) | EP4054581A4 (enExample) |
| JP (1) | JP7635228B2 (enExample) |
| KR (1) | KR102938141B1 (enExample) |
| CN (1) | CN114929226B (enExample) |
| AU (1) | AU2020378345A1 (enExample) |
| BR (1) | BR112022008821A2 (enExample) |
| CA (1) | CA3160637A1 (enExample) |
| CL (1) | CL2022001178A1 (enExample) |
| CO (1) | CO2022007814A2 (enExample) |
| GE (1) | GEP20257840B (enExample) |
| IL (1) | IL292785B2 (enExample) |
| MX (1) | MX2022005563A (enExample) |
| PH (1) | PH12022551105A1 (enExample) |
| TW (1) | TWI882032B (enExample) |
| UA (1) | UA129894C2 (enExample) |
| WO (1) | WO2021092246A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20250048T1 (hr) | 2018-10-22 | 2025-03-28 | Alumis Inc. | Inhibitori tyk2 i njihova uporaba |
| MX2021009555A (es) * | 2019-02-07 | 2021-10-13 | Ventyx Biosciences Inc | Ligandos de pseudocinasa tyk2. |
| IL286248B2 (en) * | 2019-03-11 | 2025-12-01 | Alumis Inc | Tyk2 inhibitors and uses thereof |
| EA202192625A1 (ru) | 2019-03-26 | 2022-03-21 | Вентикс Байосайенсес, Инк. | Лиганды псевдокиназы tyk2 |
| KR102938141B1 (ko) | 2019-11-08 | 2026-03-11 | 벤틱스 바이오사이언스, 인크. | Tyk2 슈도키나제 리간드 |
| CA3167339A1 (en) | 2020-01-13 | 2021-07-22 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| WO2024011136A1 (en) * | 2022-07-06 | 2024-01-11 | Ventyx Biosciences, Inc. | Crystalline forms of a tyk2 inhibitor |
| EP4649082A1 (en) * | 2023-01-13 | 2025-11-19 | Ventyx Biosciences, Inc. | Preparation of a tyk2 inhibitor |
| CN117247389A (zh) * | 2023-09-18 | 2023-12-19 | 南京友怡医药科技有限公司 | 一种靶向药物化合物及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| KR20050115252A (ko) | 2003-02-28 | 2005-12-07 | 데이진 화-마 가부시키가이샤 | 피라졸로[1,5-ａ]피리미딘 유도체 |
| US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| BRPI0616985B1 (pt) * | 2005-10-06 | 2021-10-26 | Merck Sharp & Dohme Corp. | Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto |
| US8591943B2 (en) * | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
| KR102015402B1 (ko) | 2010-05-20 | 2019-08-28 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
| TWI744256B (zh) | 2015-11-06 | 2021-11-01 | 美商英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物 |
| KR102477063B1 (ko) | 2016-10-28 | 2022-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물 |
| TWI868528B (zh) | 2017-03-08 | 2025-01-01 | 日商武田藥品工業股份有限公司 | Ｔｙｋ２抑制劑之生產方法 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US20200360381A1 (en) | 2017-05-15 | 2020-11-19 | Dana-Farber Cancer Institute, Inc. | Compounds for treating dengue virus infection and other viral infections |
| WO2019023468A1 (en) * | 2017-07-28 | 2019-01-31 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| ES2938751T3 (es) | 2018-09-10 | 2023-04-14 | Lilly Co Eli | Derivados de pirazol[1,5-a]pirimidina-3-carboxamida útiles en el tratamiento de la psoriasis y el lupus eritematoso sistémico |
| CA3115088A1 (en) | 2018-10-15 | 2020-04-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| AR117177A1 (es) | 2018-12-10 | 2021-07-14 | Lilly Co Eli | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa |
| MX2021009555A (es) | 2019-02-07 | 2021-10-13 | Ventyx Biosciences Inc | Ligandos de pseudocinasa tyk2. |
| IL286248B2 (en) | 2019-03-11 | 2025-12-01 | Alumis Inc | Tyk2 inhibitors and uses thereof |
| EA202192625A1 (ru) | 2019-03-26 | 2022-03-21 | Вентикс Байосайенсес, Инк. | Лиганды псевдокиназы tyk2 |
| KR102938141B1 (ko) | 2019-11-08 | 2026-03-11 | 벤틱스 바이오사이언스, 인크. | Tyk2 슈도키나제 리간드 |
-
2020
- 2020-11-05 KR KR1020227018394A patent/KR102938141B1/ko active Active
- 2020-11-05 TW TW109138709A patent/TWI882032B/zh active
- 2020-11-05 PH PH1/2022/551105A patent/PH12022551105A1/en unknown
- 2020-11-05 AU AU2020378345A patent/AU2020378345A1/en active Pending
- 2020-11-05 GE GEAP202015969A patent/GEP20257840B/en unknown
- 2020-11-05 IL IL292785A patent/IL292785B2/en unknown
- 2020-11-05 CA CA3160637A patent/CA3160637A1/en active Pending
- 2020-11-05 US US17/090,805 patent/US11753411B2/en active Active
- 2020-11-05 JP JP2022525957A patent/JP7635228B2/ja active Active
- 2020-11-05 BR BR112022008821A patent/BR112022008821A2/pt unknown
- 2020-11-05 EP EP20884019.9A patent/EP4054581A4/en active Pending
- 2020-11-05 CN CN202080092581.XA patent/CN114929226B/zh active Active
- 2020-11-05 MX MX2022005563A patent/MX2022005563A/es unknown
- 2020-11-05 UA UAA202201178A patent/UA129894C2/uk unknown
- 2020-11-05 WO PCT/US2020/059210 patent/WO2021092246A1/en not_active Ceased
-
2022
- 2022-05-04 CL CL2022001178A patent/CL2022001178A1/es unknown
- 2022-06-01 CO CONC2022/0007814A patent/CO2022007814A2/es unknown
-
2023
- 2023-07-06 US US18/348,296 patent/US20230348478A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN114929226A (zh) | 2022-08-19 |
| CL2022001178A1 (es) | 2023-02-03 |
| TW202128698A (zh) | 2021-08-01 |
| US11753411B2 (en) | 2023-09-12 |
| UA129894C2 (uk) | 2025-09-03 |
| EP4054581A1 (en) | 2022-09-14 |
| KR102938141B1 (ko) | 2026-03-11 |
| IL292785B2 (en) | 2025-09-01 |
| US20230348478A1 (en) | 2023-11-02 |
| IL292785B1 (en) | 2025-05-01 |
| CN114929226B (zh) | 2024-09-27 |
| MX2022005563A (es) | 2022-08-19 |
| CO2022007814A2 (es) | 2022-09-09 |
| CA3160637A1 (en) | 2021-05-14 |
| TWI882032B (zh) | 2025-05-01 |
| WO2021092246A1 (en) | 2021-05-14 |
| JP2022553841A (ja) | 2022-12-26 |
| KR20220107194A (ko) | 2022-08-02 |
| PH12022551105A1 (en) | 2023-11-20 |
| JP7635228B2 (ja) | 2025-02-25 |
| EP4054581A4 (en) | 2023-11-22 |
| US20210139486A1 (en) | 2021-05-13 |
| AU2020378345A1 (en) | 2022-06-02 |
| IL292785A (en) | 2022-07-01 |
| BR112022008821A2 (pt) | 2022-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500500A1 (en) | Pyrazolopyrimidinone compounds and uses thereof | |
| SA519402217B1 (ar) | مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون | |
| MX2025009223A (es) | Agentes de union a clec9a y su uso | |
| MX2025008493A (es) | Agentes de union a fibroblastos y uso de estos | |
| MX2021005348A (es) | Compuestos de piridazinonas y usos de los mismos. | |
| PH12022551105A1 (en) | Tyk2 pseudokinase ligands | |
| MX2020001187A (es) | Composiciones y métodos para la administración de virus adenoasociados. | |
| MX2021009555A (es) | Ligandos de pseudocinasa tyk2. | |
| PH12020550051A1 (en) | Glp-1 compositions and uses thereof | |
| MX2019001920A (es) | Arn la terapia contra el cancer. | |
| MX2020014031A (es) | Proteinas heterodimericas y usos de las mismas. | |
| SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
| MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| GEP20247585B (en) | Furoindazole derivatives | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
| CR20230177A (es) | Compuestos y composiciones como moduladores de señalización tlr | |
| MY207469A (en) | Therapeutic compounds | |
| MX2020009566A (es) | Compuestos como moduladores de la se?alizacion de tlr2. | |
| PH12021552358A1 (en) | Compounds and compositions as modulators of tlr signaling | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| MX2019002284A (es) | Sistemas de deposito que comprenden acetato de glatiramer. | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2021015333A (es) | Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4. |